Outlook Therapeutics Inc - Lytenava™ (Bevacizumab Gamma) Receives Ten Years of Market Exclusivity in EU
Outlook Therapeutics Inc-Lytenava™(Bevacizumab Gamma)在歐盟獲得十年的市場獨家經營權
Outlook Therapeutics Inc - Lytenava™ (Bevacizumab Gamma) Receives Ten Years of Market Exclusivity in EU
Outlook Therapeutics Inc-Lytenava™(Bevacizumab Gamma)在歐盟獲得十年的市場獨家經營權
譯文內容由第三人軟體翻譯。